DARE

Dare Bioscience, Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$0.78

+$0.04+4.81%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

Aug 24, 2026$0.78

−$0.02−2.24%over 1M

Session

Day range41% of range

$0.77$0.81

Fundamentals

Visualize fundamentals and more

Market cap: 11.67M
P/E ratio: -

Revenue grew +10429.36% in FY2025, +10420.50% faster than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 57
dropped: 58
re-drafted: 47

Out of 298 passages in this year’s Item 1A.

New this year

• We will need to raise substantial additional capital to continue our operations, execute our business strategy and remain a going concern, and we may not be able to raise adequate capital on a timely basis, on favorable terms, or at all. Raising additional …

114 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Going concern
Dilution
Litigation
Product recalls
Supplier concentration
Commodity prices

And 13 more.

FDA approval
Our business depends on obtaining the approval of regulatory authorities, and in particular, FDA approval, to market products that we develop. All of our product candidates are investigational, require the conduct and successful completion of clinical studies …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

32 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Dare Bioscience, Inc. investor relations

What DARE has filed with the SEC. This is not Dare Bioscience, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Dare Bioscience, Inc.

Also filed under Biotechnology, ranked by how closely they sit beside DARE.

MRNAModerna, Inc.compare with DARE
ROIVRoivant Sciences Ltd.compare with DARE
VRTXVertex Pharmaceuticals Inc. / MA

XENEXenon Pharmaceuticals Inc.compare with DARE

NVONovo Nordisk A Scompare with DARE

Ask about Dare Bioscience, Inc.

The assistant answers from what DARE has actually filed: 14 annual reports filed with the SEC, 5 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from DARE's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Dare Bioscience, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Dare Bioscience, Inc.

Be told the moment a DARE insider trades
Put Dare Bioscience, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Dare Bioscience, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Dare Bioscience, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Going concern
Dilution
Litigation
Product recalls
Supplier concentration
Commodity prices

And 13 more.

FDA approval
Our business depends on obtaining the approval of regulatory authorities, and in particular, FDA approval, to market products that we develop. All of our product candidates are investigational, require the conduct and successful completion of clinical studies …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 57
dropped: 58
re-drafted: 47

Out of 298 passages in this year’s Item 1A.

New this year

• We will need to raise substantial additional capital to continue our operations, execute our business strategy and remain a going concern, and we may not be able to raise adequate capital on a timely basis, on favorable terms, or at all. Raising additional …

114 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add